Related Experiment Video

Updated: Jul 18, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Optimizing therapy of seizures in children and adolescents with developmental disabilities

Michael C Smith1

  • 1Rush Epilepsy Center, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. msmith@rush.edu

Neurology
|December 28, 2006
PubMed

Insights

Children and adolescents with intellectual and developmental disabilities (IDD) and epilepsy face unique challenges, including intractable seizures and difficulty communicating antiepileptic drug (AED) side effects. Caregiver advocacy and consideration of behavioral comorbidities are crucial for effective treatment.

Area of Science:

  • Neurology
  • Developmental Pediatrics
  • Clinical Pharmacy

Background:

  • Children and adolescents with intellectual and developmental disabilities (IDD) and epilepsy represent a vulnerable patient group.
  • This population frequently experiences intractable epilepsy with diverse seizure types.
  • Communication barriers regarding antiepileptic drug (AED) side effects are common, necessitating caregiver involvement.

Purpose of the Study:

  • To highlight the complex challenges in managing epilepsy in pediatric patients with IDD.
  • To emphasize the critical role of caregivers in patient advocacy.
  • To underscore the importance of considering behavioral and psychiatric comorbidities in AED selection.

Main Methods:

  • Review of existing literature on epilepsy management in IDD.
  • Analysis of challenges in patient-physician communication.
  • Consideration of comorbidity impact on treatment.

Main Results:

  • Patients with IDD and epilepsy often have lifelong, intractable seizure disorders.
  • Caregivers are essential for reporting AED side effects.
  • Behavioral and psychiatric issues are prevalent and influence AED choice.

Conclusions:

  • Effective epilepsy management in children with IDD requires a multidisciplinary approach.
  • Caregiver education and empowerment are vital for optimal outcomes.
  • Personalized AED selection considering comorbidities is paramount for this unique patient population.

More Related Videos

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...